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2
The study of biliary disease has been constrained by a lack of primary 3
human cholangiocytes. Here we present an efficient, serum-free 4
protocol for directed differentiation of human induced pluripotent stem 5
cells into cholangiocyte-like cells (CLCs). CLCs show functional 6
characteristics of cholangiocytes, including bile acids transfer, alkaline 7
phosphatase activity, gamma-glutamyl-transpeptidase activity and 8
physiological responses to secretin, somatostatin and VEGF. We use 9
CLCs to model in vitro key features of Alagille syndrome, polycystic 10
liver disease and cystic fibrosis (CF)-associated cholangiopathy.11
Furthermore, we use CLCs generated from healthy individuals and 12
patients with polycystic liver disease to reproduce the effects of the13
drugs verapamil and octreotide, and we show that the experimental CF14
drug VX809 rescues the disease phenotype of CF cholangiopathy in 15
vitro. Our differentiation protocol will facilitate the study of biological16
mechanisms controlling biliary development as well as disease 17
modeling and drug screening.18
19
4Cholangiocytes are the main target of cholangiopathies, a diverse group of 1
bile duct disorders that includes inherited diseases such as CF-associated 2
cholangiopathy, developmental diseases such as Alagille Syndrome and3
autoimmune diseases such as primary biliary cirrhosis, as well as drug- and4
toxin-induced conditions (1). Cholangiopathies carry significant morbidity and 5
mortality, accounting for up to a third of adult and >70% of pediatric liver 6
transplantations (2). However, research on their pathophysiology has been 7
limited by poor access to primary biliary tissue, difficulties in culturing primary 8
cholangiocytes in vitro and inadequate animal disease models(3). The 9
capacity of human induced pluripotent stem cells (hiPSCs) to proliferate 10
indefinitely in culture and differentiate into a broad spectrum of cell types 11
makes them well suited to in vitro disease modeling (5). Early methods for12
deriving cholangiocytes from hiPSCs (6) were based on spontaneous 13
differentiation and had limited characterization of the resulting cells (7-8).14
Despite recent advances toward guided differentiation of hiPSCs to CLCs (9),15
current protocols show poor differentiation efficiency (<31%), and the derived 16
cells differ considerably from primary biliary tissue in their transcriptional 17
profiles. Furthermore, in vitro-generated cholangiocytes have not been shown18
to reproduce key functions of bona fide cholangiocytes, such as enzymatic19
activity (e.g., alkaline phosphatase (ALP) and gamma glutamyl transferase 20
(GGT)), responses to hormonal stimuli (secretin and somatostatin) and 21
chloride transfer (CFTR) function (7-9). Demonstration of these properties is22
essential for recapitulating cholangiopathies and studying the effects of 23
therapeutic agents. Finally, current systems diverge from the physiological 24
5pathways controlling biliary development in vivo (7-9), limiting their value for 1
developmental studies.2
3
Here we report a stepwise method for cholangiocyte differentiation that 4
recapitulates native biliary development (Fig. 1a). The quality, functionality 5
and purity of the resulting CLCs is substantially higher compared to cells 6
generated by previous methods (see Supplementary Note and Supplementary 7
Figure 1 for detailed comparison).8
9
Results10
Cholangiocyte progenitors generated from hiPSCs 11
We focused first on the generation of bipotent hepatoblasts, the common 12
progenitor of hepatocytes and cholangiocytes (10). To achieve this goal, we 13
adapted our established hepatic hiPSC differentiation protocol (11-12). Cells 14
generated with the adapted protocol after 12 days of differentiation express 15
hepatoblast markers, including AFP, HNF4A, HNF1B, TBX3, and CK1916
(Figure 1b,1d), and have the potential to differentiate toward both the hepatic 17
(Supplementary Figure 2a-2c) and biliary lineages (Figure 1c-1d, 18
Supplementary table 1). To differentiate these hepatoblast-like cells into 19
cholangiocyte progenitors (CPs), we interrogated pathways reported to 20
control early biliary specification (10) (Supplementary Fig 3a-3c and data not 21
shown) and found that activin in combination with retinoic acid suppressed the 22
expression of the hepatoblast markers AFP, HNF4A and TBX323
(Supplementary Figure 3c). Addition of FGF10 along with activin and retinoic 24
acid [AU: OK?] induced the expression of the early biliary specification 25
6markers SOX9, HNF1B and CK19 (Figure 1c-1d) (10), resulting in a 1
population in which 75.1% of cells were CK19+/Sox9+ (Supplementary Figure2
4a). Flow cytometry analyses identified the majority of the remaining cells as 3
Sox9-/AFP+ hepatoblasts (Supplementary Figure 4a), explaining the 4
presence of reduced but detectable AFP levels in our culture (Figure 1d). 5
Mature biliary markers such as Secretin Receptor (SCR), Somatostatin 6
Receptor 2 (SSTR2), Aquaporin1 and Anion Exchanger 2 (AE2) were not 7
expressed (Figure 1d). Thus, activin, retinoic acid and FGF10 promote the 8
differentiation of hepatoblast-like cells into early CLCs or cholangiocyte 9
progenitors (CPs) in vitro. 10
11
To promote maturation of the CPs, we used 3D culture conditions 12
known to induce cholangiocyte maturation through organoid formation (7-9). 13
CPs grown in these conditions proliferated rapidly, organized into ring-like 14
structures after 48-72 hours and within 5-7 days gave rise to cystic organoids 15
and branching tubular structures (Figure 2a-2b) bearing primary cilia (Figure 16
2c) similar to those of primary cholangiocytes. The organoids expressed 17
biliary markers, including CK7, CK18, CK19, HNF1B, Gamma Glutamyl-18
Transferase (GGT), Jagged1 (JAG1), NOTCH2, CFTR, SCR, SSTR2, 19
Aquaporin1 and Anion Exchanger 2 (Figure 1d,2d) at levels similar to primary 20
cholangiocytes (Figure 1d, Supplementary Figure 5). Transcriptomic analyses 21
of common bile duct primary tissue and cells at key stages of our 22
differentiation protocol (Supplementary Table 2, Figure 2e) using Euclidian 23
hierarchical clustering revealed that CLCs are distinct from earlier 24
developmental stages (Figure 2e, Supplementary Figure 6), cluster closely25
7with primary common bile duct cholangiocytes (Pearson correlation coefficient 1
for CLCs vs. CBD r = 0.747, CLCs vs. HBs r = 0.576, CLCs vs. hiPSCs: r = 2
0.474) and express both mature (SSTR2, ALP, KRT7) and fetal (SOX9) biliary 3
markers, as shown by IF and QPCR analyses (Figure 2e, Supplementary 4
Figure 6). These results confirm that CPs can differentiate into cells 5
resembling biliary epithelial cells when grown in 3D culture.6
7
The efficiency of our differentiation protocol can be estimated from the 8
observation that 1x10
6
hiPSCs produce by day 26 ~74.4x10
6
cells, of which 9
~57.28x10
6
express mature biliary markers (~74.4x10
6
cells generated X 77% 10
(average differentiation efficiency across 3 lines, SD=6.5%) = ~57.28x10
6
11
CLCs) (Supplementary Figure 4a-b). More specifically, 74.5% of the resulting 12
cells co-express the biliary marker Sox9 and the mature biliary marker CK713
(Supplementary Figure 4a). A further 7.5% of the cells express Sox9 but not 14
CK7, consistent with immature cholangiocytes (Supplementary Figure 4a).15
15% of the cells co-express AFP and Albumin (Supplementary Figure 4a),16
indicating the presence of a small fraction of hepatocytes in our culture 17
conditions and explaining the detection of low AFP levels by QPCR analyses18
(Figure 1d). The remaining 3% of the cells were not characterized further.19
These results were confirmed on 3 independent hiPSC lines (Supplementary 20
Figure 4a). 21
22
Next, we characterized the functionality of the generated organoids. In 23
vivo, cholangiocytes re-absorb bile acids (13) and modify the composition of 24
canalicular bile through a series of secretory and re-absorptive processes (14) 25
8regulated by intracellular calcium signaling (15). Native biliary epithelial cells 1
have ALP and GGT activity and proliferate in response to stimuli such as 2
Vascular Endothelial Growth Factor (VEGF). The secretory potential of CLCs 3
generated in vitro was confirmed using Rhodamine123, a fluorescent 4
substrate for the cholangiocyte surface glycoprotein multidrug resistance 5
protein-1 (MDR1) (16-17).  Rhodamine123 was actively secreted in the lumen 6
of CLC organoids; however, luminal dye accumulation was prevented by the 7
MDR1 inhibitor verapamil (Figure 3a-3c), confirming MDR1-dependent 8
transfer of Rhodamine123. The capacity of CLCs for interacting with bile acids 9
through the apical salt and bile transporter (ASBT) (13) was demonstrated by 10
showing active export of the fluorescent bile acid cholyl-lysyl-fluorescein 11
(CLF) from the lumen of CLF-loaded organoids compared to controls loaded 12
with Fluorescein Isothiocyanate (FITC) (Figure 3d-3f, Supplementary Video 13
1,2). ASBT expression was confirmed by QPCR and IF analyses 14
(Supplementary Figure 7a-7b). Furthermore, CLCs responded to 15
acetylcholine and ATP stimuli by increasing intracellular calcium levels (Figure 16
3g, Supplementary video 3,4), demonstrated increased proliferation in 17
response to VEGF stimulation (51% increase in fold expansion, P<0.0001, 2-18
tailed t-test) (Figure 3h-3i) and exhibited GGT and ALP activities similar to 19
those of primary controls (GGT activity: 160% of human serum, P<0.0001, 20
one-way ANOVA with Dunnett correction for multiple comparisons) (Figure 3j-21
3k). Together, these observations confirm that our hiPSC-derived CLCs 22
display a range of functions of the native biliary epithelium.23
24
CLCs model development of the human biliary system 25
9To investigate potential applications of our system for developmental studies, 1
we characterized signaling pathways that control organoid formation in vitro2
as compared with native duct development. First, we interrogated 3
Activin/TGFβ signaling in view of its pivotal role in physiological biliary 4
specification and tubulogenesis (10, 18-19). We blocked the activity of TGFβ, 5
which is normally present in Matrigel, using the Activin receptor inhibitor SB-6
431542. SB-431542 completely abrogated organoid formation (Figure 4a, 4b) 7
confirming the role of Activin/TGFβ signaling as a key regulator of organoid 8
formation in our system.  9
10
We performed similar analyses for Notch signaling during biliary 11
specification of hepatoblasts to CPs and CLC organoid formation in vitro.12
Deregulation of Notch signaling is associated with Alagille Syndrome (AGS), 13
characterized by a paucity of bile ducts (20). To explore the hypothesis that 14
blocking Notch signaling would impair organoid formation in vitro, we first 15
characterized the activity of the Notch pathway in our system. Notch activation 16
results in cleavage and nuclear translocation of its intracellular domain (21-17
23). Immunofluorescence (IF) analysis with antibodies specific to the cleaved 18
Notch intracellular domain (NICD) confirmed the presence of active NICD, 19
with increased nuclear localization in CPs (Supplementary Figure 8) and CLC 20
organoids (Figure 4d). The expression of NOTCH2, as well as its ligand JAG1 21
and its downstream target HES1, were also increased in both stages22
compared to hepatoblasts, consistent with pathway activation (CPs vs. HBs: 23
NOTCH2: P<0.001, JAG1: P<0.001, HES1: P<0.05; CLCs vs. CPs or HBs: 24
P<0.0001) (Figure 1d). Inhibition of Notch signaling in 3D culture conditions 25
10
using the gamma-secretase inhibitor L-685,458 blocked cleavage of the 1
NICD, suppressed HES1, NOTCH2 and JAG1 expression (Figure 4c) and 2
blocked organoid formation (Figure 4e-4f), confirming the importance of Notch 3
signaling for the generation of organoids incorporating a luminal space in our 4
system. 5
6
These results reinforce previous findings obtained in mice by 7
demonstrating the importance of Activin/TGFβ and Notch signaling pathways 8
in human cholangiocyte specification (24) and underline the potential of our 9
culture system for studying human biliary tree development in vitro.10
11
CLCs validate drugs for polycystic liver diseases12
Polycystic liver diseases are characterized by multiple cystic lesions in the 13
liver arising from fetal cholangiocytes (25-26). Intraluminal fluid secretion and 14
cholangiocyte proliferation result in cyst expansion and liver impairment owing15
to space-occupying effects (27-28). We explored the use of CLC organoids to 16
identify compounds that might reduce cyst size in PLD. The secretory activity17
of cholangiocytes is increased by the hormone secretin and reduced by the 18
hormone somatostatin, resulting in changes in duct size. Octreotide, a 19
synthetic analog of somatostatin, is used clinically to restrict cyst size in 20
polycystic liver disease (28-32). CLC organoids express both SCR and21
SSTR2 (Figure 1d, 5a–5b) suggesting that these pathways may be functional 22
in our cells. Accordingly, secretin increased organoid size (6.1% average 23
diameter increase, P<0.01, one-way ANOVA with Dunnett correction for 24
multiple comparisons), whereas somatostatin and octreotide decreased 25
11
organoid size, compared to untreated controls (7.9% and 4.9% average 1
diameter decrease respectively, p<0.001 and p<0.05 respectively, one-way 2
ANOVA with Dunnett correction for multiple comparisons) (Figure 5c-5d, 3
Supplementary video 5-7). Furthermore, octreotide negated the effects of 4
secretin and decreased intracellular cAMP levels (45% of somatostatin 5
response, P=0.001, one-way ANOVA with Dunnett correction for multiple 6
comparisons), in keeping with previous studies (26,30) (Figure 5e). To further 7
test the effects of octreotide on disease-specific CLCs, we differentiated 8
hiPSCs derived from a patient with polycystic liver disease (Supplementary 9
Figure 9) to CLCs (Figure 5f). Octreotide treatment reduced organoid size10
(4.86%, P<0.0001, one-way ANOVA with Dunnett correction for multiple 11
comparisons) (Figure 5g-5h), reproducing the effects of the drug in vitro. 12
13
CLCs model CF Liver Disease 14
The autosomal recessive disorder CF is caused by mutations in the cystic 15
fibrosis transmembrane conductance regulator gene (CFTR), a cell-surface 16
chloride transporter (33-34). CFTR mutations in cholangiocytes result in 17
reduced intra-luminal chloride secretion, increased bile viscosity, and focal 18
biliary cirrhosis secondary to bile plugs occluding the intrahepatic bile ducts 19
(35-36). To model CF biliary disease in vitro, we generated hiPSCs from skin 20
fibroblasts of a patient homozygous for the most common CF mutation ΔF50821
(CF- hiPSC) (37) and differentiated them into CLCs. CF-hiPSC-derived CLCs22
(CF-CLCs) expressed markers (Figure 6a) and displayed functional 23
characteristic of biliary epithelial cells (Figure 6b). Transcription of the CFTR24
gene was confirmed using QPCR (Figure 6a), and IF analyses detected 25
12
minimal CFTR protein expression (Figure 6c), in agreement with studies 1
reporting very rapid ER degradation of the misfolded protein (38). We also 2
used the fluorescent chloride indicator N-(6-methoxyquinolyl)acetoethyl ester 3
(MQAE) (39) to monitor intracellular and intraluminal chloride concentration. 4
Wild-type (WT) CLC organoids appropriately modified intracellular chloride in 5
response to media with varying chloride concentration, whereas no change 6
was observed in CF-CLCs (Figure 6d,6e), confirming the absence of 7
functional CFTR in these cells. 8
9
Next we investigated the effects of the experimental CF drug VX809 10
(41) in the context of biliary disease. VX809 stabilizes CFTR, corrects folding 11
defects in patients with the ΔF508 mutation and increases CFTR functionality 12
in lung cells (42). Incubation of CF-CLCs with VX809 for 48 hours increased 13
CFTR function analyzed by MQAE to a level similar to that of WT-CLCs14
(Figure 6d, 6e). This effect was negated by the CFTR inhibitor-172, confirming 15
that the phenotypic rescue of CF-CLCs by VX809 was dependent on 16
improved CFTR function (Figure 6d, 6e).17
Given the association between chloride and fluid secretion in cholangiocytes 18
(33), we studied the impact of VX809 on organoid size. CF-CLC organoids 19
treated with VX809 increased in size compared to their untreated counterparts20
(5.6% mean diameter increase, P=0.001, 2-tailed t-test) (Figure 6f, 6g). This21
observation confirmed that VX809 increases CFTR function and improves 22
intraluminal fluid secretion, suggesting a previously unreported therapeutic 23
effect for this drug in the context of CF liver disease. 24
25
13
Discussion1
We present a protocol for the generation of CLCs from hiPSCs that addresses2
the limitations of previously published differentiation methods by more closely3
recapitulating natural bile duct development (Fig. 1a). Our results confirm the 4
importance of FGF10 and activin/TGFβ for early biliary specification, as 5
previously described in vivo (10,19,43), and reveal a role for retinoic acid in 6
this process, at least in vitro [AU: OK?]. We show that the combination of 7
these factors under chemically defined, serum-free conditions is sufficient to 8
promote the specification of hiPSC-derived hepatoblasts into cholangiocyte 9
progenitors with high efficiency. Production of cholangiocyte progenitors, 10
mimicking physiological biliary development, has not been demonstrated11
previously and likely explains the efficiency of our culture system in 12
generating CLCs that closely resemble bona fide cholangiocytes at the 13
transcriptional (Supplementary Figure1, Supplementary table 3, 4) and 14
functional levels (Supplementary table 3). 15
16
Our protocol will enable various applications such as developmental studies, 17
disease modeling, therapeutic target validation and drug screening. The 18
pharmaceutical applications of our system are particularly important given the 19
lack of high-throughput drug screening platforms for cholangiopathies. We 20
used patient-derived hiPSCs to model polycystic and CF liver disease and 21
applied these models to reproduce the effects of the therapeutic compounds 22
verapamil, octreotide and VX809. VX809 has already completed phase IIa 23
clinical trials (42) for CF, but its effects on CF-associated cholangiopathy have 24
not been described. Our results suggest that CLCs provide a suitable system 25
14
for identifying novel therapeutic agents. CLCs may also contribute to tissue 1
engineering of livers or liver organoids that incorporate a biliary system for the 2
treatment of end-stage disease.3
15
Online Methods1
Generation of hiPSC lines2
All the hiPSC lines used here were derived and characterized previously by 3
our lab (11, 37). Briefly, the lines used were generated from human skin 4
fibroblasts and peripheral blood (ethics reference no. 08/H0311/201 and 5
09/H0304/77 respectively), using the Yamanaka approach (4, 9). The CF 6
fibroblasts were obtained from the Coriell cell repository. The lines were 7
authenticated using SNIP arrays and regularly tested negative for 8
mycoplasma contamination.9
Culture of hiPSCs10
Human iPS cells were maintained in defined culture conditions as previously 11
described (11-12, 44), using activin-A (10ng/ml) and b-FGF (12ng/ml).12
Differentiation of hiPSCs into cholangiocyte progenitors.13
hiPSCs were differentiated into Foregut Progenitor cells (FP) as previously 14
described (12, 44). Bipotent hepatoblasts were generated by culturing FPs in 15
RPMI (Gibco, Invitrogen) + B27 supplemented with SB-431542 (10μM, Tocris 16
Bioscience) and BMP4 (50ng/ml) for 4 days. To induce biliary specification, 17
we cultured hepatoblasts for another 4 days in the presence of RPMI (Gibco, 18
Invitrogen) + B27 supplemented with FGF10 (50ng/ml, Peprotech), activin-A 19
(50ng/ml) and RA (3μM, Sigma-Aldrich). 20
Maturation of cholangiocyte progenitor cells to CLCs and organoid 21
formation in 3D culture.22
Human CPs were passaged using Cell Dissociation Buffer (Gibco, Life 23
Technologies) and suspended at a density of 8 X 10
4
cells/ml, in a mixture of 24
40% matrigel (BD Biosciences, catalogue number: 356237) and 60% 25
16
William’s E medium (Gibco, Life Technologies) supplemented with 10mM 1
nicotinamide (Sigma-Aldrich), 17mM sodium bicarbonate (Sigma Aldrich), 2
0.2mM 2-Phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich), 6.3mM 3
sodium pyruvate (Invitrogen), 14 mM glucose (Sigma-Aldrich), 20 mM HEPES 4
(Invitrogen), ITS+ premix (BD Biosciences), 0.1uM dexamethasone (R&D 5
Systems), 2mM Glutamax (Invitrogen),100U/ml penicillin per 100μg/ml 6
streptomycin and 20ng/ml EGF (R&D Systems). A 50μL droplet of the cell 7
suspension was added in the centre of each well of a 24-well plate; the gel 8
was allowed 1 hour at 37
o
C to solidify and then overlaid with William’s E 9
medium with supplements. The medium was changed every 48 hours and the 10
cells were cultured for a total of 10 days.11
Importantly, using the same methodology, we have been able to culture CLC 12
organoids in multiple formats ranging from 6 to 96 well plates. To generate 13
large numbers of CLC organoids, multiple 50μL droplets were added in a well 14
of a 6 well plate or a 10cm dish. To provide a large number of wells 15
compatible with high throughput screening and large scale experiments 30μL 16
droplets were added in a well of a 96 well plate. In both cases, the gel was 17
allowed 1 hour at 37
o
C to solidify and then overlaid with William’s E medium 18
with supplements. 19
Inhibition of activin and Notch signaling in 3D culture and assessment 20
of organoid formation.21
Human CPs were suspended at a density of 8 X 10
4
cells/ml, in a mixture of 22
40% matrigel and 60% William’s E medium (Gibco, Life Technologies) with 23
supplements as described above. The cell suspension was distributed in 3 24
equal volume aliquots. One aliquot received no further supplementation and 25
17
was used as a positive control. The second aliquot was further supplemented 1
by 10μM SB-431542 for the inhibition of TGFβ/activin signaling. 50μM of L-2
685,458 (Tocris Biosciences) were added in the third aliquot for the inhibition 3
of Notch signaling. Each aliquot was distributed in 24-well plate format. The 4
same concentrations of inhibitors were added to the medium overlaying the 5
matrigel on a daily basis. After a total of 10 days in 3D culture, the total 6
number of cysts in 4 random wells of a 24 well plate was counted for each 7
condition by a blinded researcher. Error bars represent SD.8
Flow cytometry analyses9
HiPSCs, FPs, HBs and CPs were dissociated to single cells using Cell 10
Dissociation Buffer (Life Technologies).  The cells were subsequently counted 11
using a hemocytometer and fixed using 4% PFA for 20 minutes at 4
o
C. Cell 12
staining and flow cytometry analyses were performed as previously described 13
(44).14
CLC organoids were washed once with PBS and 1ml of ice cold dispace was 15
added per well of a 24 well plate. The matrigel was mechanically dissociated, 16
transferred in a falcon tube and kept on ice to allow the combination of low 17
temperature and dispase digestion to liquefy the matrigel.  After 10 minutes 18
the cells were centrifuged at 1600 rpm for 3 minutes and the supernatant was 19
aspirated. The pellet was washed once with PBS and the centrifugation step 20
repeated. The supernatant was aspirated and 1 ml of TrypLE (Life 21
technologies) was added for 3-5 minutes until the organoids were dissociated 22
to single cells. Finally, the single cell suspension was centrifuged at 1600 rpm 23
for 3 minutes, and fixed using 4% PFA for 20 minutes at 4
o
C. Cell staining 24
and flow cytometry analyses were performed as previously described (44).25
18
Primary cholangiocytes1
Frozen primary human cholangiocytes derived from common bile duct were 2
obtained from Celprogen (Catalogue Number 36755-11). The cells were 3
derived from donors negative for Hepatitis B Surface Antigen, HIV1 and 2, 4
Syphilis, Hepatitis B Virus, Human T Lymphocyte Virus 1 and 2, Hepatitis C 5
Virus, HIV 1, West Nile Virus and Trypanosoma cruzi.  Each frozen ampule 6
(1.2 x 10
6 
cells) of 1 x 10
6 
viable cells was thawed with gentle agitation in a 7
37°C water bath. The cells were transferred to a sterile centrifuge tube and 1 8
ml of pre-warmed Human Cholangiocyte Cell Culture Complete Growth Media 9
(catalogue number M36755-11S) was added. The ampule was washed twice 10
with Human Cholangiocyte Cell Culture Complete Growth Media and the cells 11
were centrifuged at 100g for 7 minutes. The pellet was subsequently re-12
suspended in 500ul of Human Cholangiocyte Cell Culture Complete Growth 13
Medium. The cells were distributed equally to 2 wells of a 6 well plate pre-14
coated with Human Cholangiocyte Cell Culture Extracellular Matrix (catalogue 15
number M36755-11-6-wells) with 2ml of Human Cholangiocyte Cell Culture 16
Complete Growth Medium per well. The cells were incubated at 37°C in a 5% 17
CO2 humidified incubator for 48 hours and the media was changed once. 18
After another 24 hours, when the wells were confluent the cells were lysed 19
and RNA was extracted as previously described (11-12), or fixed with 4% PFA 20
as previously described (11-12) for ALP staining. QPCR analyses for biliary 21
markers (Figure 1d) and ALP staining (Figure 3k) confirmed the nature and 22
cholangiocyte properties of the cells.23
Primary biliary tissue24
19
Primary biliary tissue (bile duct) was obtained from an organ donor. The liver 1
and pancreas from the donor were being retrieved for transplantation. A 2
section of the bile duct was excised during the multi-organ retrieval operation 3
after obtaining informed consent from the donor's family (REC reference 4
number: 09/H0306/73). The tissue was homogenized using a tissue 5
homogenizer and RNA was extracted as previously described (11).6
Immunofluorescence, RNA extraction and Quantitative Real Time PCR7
IF, RNA extraction and QPCR were performed as previously described (9). A 8
complete list of the primary and secondary antibodies used is provided in 9
supplementary table 5. A complete list of the primers used is provided in 10
supplementary table 6. All QPCR data are presented as mean values of four11
independent biological replicates, with the exception of the primary CDB 12
cholangiocytes from Celprogen, where 3 independent samples were used. 13
Error bars represent SD.14
For IF in 3D matrigel cultures, the organoids were fixed in matrigel with 4% 15
PFA for 20 minutes at room temperature, to avoid matrigel liquefaction. The 16
samples were permeabilized and blocked with 0.1% Triton-X and 10% donkey 17
serum respectively for 30 minutes and incubated with primary antibody in 1% 18
donkey serum overnight at 4
o
C. The following day the samples were washed 19
3 times with PBS for 45 minutes per wash, incubated with secondary antibody 20
in 1% donkey serum for 60 minutes at room temperature and washed again 3 21
times in PBS. Hoechst 33258 was added to the first wash.22
All IF images were acquired using a Zeiss Axiovert 200M inverted microscope 23
or a Zeiss LSM 700 confocal microscope. Imagej 1.48k software (Wayne 24
Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image processing. 25
20
Changes in brightness or contrast during processing were applied equally 1
across the entire image.2
For RNA extraction in 3D matrigel cultures, the organoids were washed once 3
with PBS and 1ml of ice cold dispace was added per well of a 24 well plate. 4
The matrigel was mechanically dissociated, transferred in a falcon tube and 5
kept on ice to allow the combination of low temperature and dispase digestion 6
to liquefy the matrigel.  After 10 minutes the cells were centrifuged at 1600 7
rpm for 3 minutes and the supernatant was aspirated. The pellet was washed 8
once with PBS and the centrifugation step repeated. Finally, the supernatant 9
was aspirated and 350μL of RNA lysis buffer were added to the pellet. RNA 10
was extracted from the lysate using a kit (Sigma-Aldrich), according to the 11
manufacturer’s instructions. 12
Microarrays13
500ng of total cellular RNA was amplified and purified using the Illumina 14
TotalPrep-96 RNA Amplification kit (Life Technologies) according to the 15
manufacturer’s instructions. Three biological replicates for each condition 16
were analysed. Biotin-Labelled cRNA was then normalized to a concentration 17
of 150ng/μl and 750ng were hybridised to Illumina Human-12 v4 BeadChips 18
for 16 hours (overnight) at 58 °C. Following hybridisation, BeadChips were 19
washed and stained with streptavidin-Cy3 (GE Healthcare). BeadChips were 20
then scanned using the BeadArray reader, and image data was then 21
processed using Genome Studio software (Illumina). The raw and processed 22
microarray data are available on ArrayExpress (Accession number: E-MTAB-23
2965, https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2965/).24
Microarrays analysis25
21
Probe summaries for all arrays were obtained from the raw data using the 1
method “Making Probe Summary”. These values were transformed (variance 2
stabilized) and quantile normalised using the R/Bioconductor package lumi 3
(45). Standard lumi QC procedure was applied and no outliers were identified.4
Differential expression between pairs of conditions was evaluated using the 5
R/Bioconductor package limma (46). A linear model fit was applied, and the 6
top differentially expressed genes were tabulated for each contrast using the 7
method of Benjamini and Hochberg to correct the p-values (47). Probes that 8
failed to fluoresce above background in both conditions were removed. 9
Differentially expressed probes were selected using a cutoff of adjusted p-10
value <0.01 and absolute fold-change > 2. 11
Probes differentially expressed between hiPSCs and CLCs or hiPSCs and 12
HBs (representing the aggregate transcriptional “signature” of CLCs and HBs) 13
were selected for Euclidean hierarchical clustering using Perseus software 14
(MaxQuant). Standard scores (z-scores) of the log2 normalized probe 15
expression values across the different conditions were calculated and used 16
for this analysis.17
Rhodamine123 transport assay18
CLC organoids were incubated with 100μM of Rhodamine 123 (Sigma-19
Aldrich) for 5 minutes at 37
o
C and the washed with William’s E medium 3 20
times. Fresh William’s E medium with supplements was added following the 21
third wash. The organoids were incubated at 37
o
C for another 40 minutes. To 22
demonstrate that Rhodamine123 transfer indeed reflected the activity of the 23
membrane channel MultiDrug Resistance Protein 1 (MDR1), CLCs were 24
incubated with 10μM of Verapamil (Sigma-Aldrich) at 37
o
C for 30 minutes and 25
22
the rhodamine assay was repeated. Following completion of each experiment, 1
images were taken using a confocal microscope. Multiple fluorescence 2
measurements were made (around 1000) between the organoid interior and 3
exterior. Rhodamine123 fluorescence in the organoid lumen was normalized 4
over background measured in the surrounding external area. Each 5
experiment was repeated in triplicate. Error bars represent SD. Mean 6
fluorescence intensity comparisons were performed using a two sided 7
student’s t-test.8
Cholyl-Lysyl-Fluorescein transport assay9
CLC organoids were loaded with 5uM of Cholyl-Lysyl-Fluorescein (CLF, 10
Corning Incorporated) for 30 minutes at 37
o
C and the washed with Leibovitz’s 11
medium (Life technologies) 3 times. Following completion of the third wash, 12
time lapse images were taken using a confocal microscope for 10 minutes. To 13
demonstrate that the changes in CLF fluorescence intensity observed were 14
secondary to active export of CLF from the organoid lumen, the experiment 15
was repeated with 5μM of unconjucated Fluorescein Isothiocyanate (FITC) 16
(Sigma-Aldrich) as a control. Multiple fluorescence measurements were made 17
(around 1000) between the organoid interior and exterior. Fluorescence in the 18
organoid lumen was normalized over background measured in the 19
surrounding external area. Each experiment was repeated in triplicate. Error 20
bars represent SD. Mean fluorescence intensity comparisons were performed 21
using a two sided student’s t-test.22
Measurement of intracellular calcium levels23
Intracellular calcium signaling, regulated by stimuli such as acetylcholine and 24
ATP constitutes a key second messenger for cholangiocytes (15). CLC 25
23
organoids were incubated with 25μM of the calcium indicator Fluo-4 AM (Life 1
technologies) for 60 minutes at 37
o
C and washed 3 times with William’s E 2
medium. Fresh William’s E medium with supplements was added following 3
the third wash. The organoids were stimulated with 1μM of Acetylcholine 4
(Sigma-Aldrich) or 30μM of ATP (Sigma-Aldrich), while time lapse images 5
were taken. Each measurement was repeated in triplicate. To calculate the 6
number of cells responding to stimulation, the number of cells loaded with 7
Fluo-4 AM was counted by 2 different researchers prior to the start of the 8
experiment. Following stimulation with ATP or acetylcholine the number of 9
responding cells (increase in fluorescence) was also counted and 10
responsiveness was expressed as the ratio of responding cells over the total 11
number of cells loaded with Fluo-4 AM. The statistical approach for smoothing 12
the data and plotting bands for the confidence limits please see ‘Statistical 13
analyses’.14
Proliferation assays15
20 50μL droplets of Matrigel, each containing 40,000 cells were distributed in 16
20 wells of a 24 well plate. VEGF at a concentration of 50ng/ml was added to 17
half of the wells with every media change. Following 5 days of culture the 18
matrigel was digested with dispase as described above (RNA extraction 19
section) and the organoids were mechanically dissociated to single cells. The 20
number of cells for each well was then counted using a haemocytometer. 20 21
different measurements were made by a blinded researcher. Primary 22
cholangiocytes distributed in 6 wells of a 12 well plate were used as a positive 23
control. 3 wells received VEGF at a concentration of 50ng/ml with every 24
media change for 5 days after which, the number of cells in each well was 25
24
counted as described above. Error bars represent SD. Mean cell number 1
comparisons were performed using a two sided student’s t-test.2
GGT activity3
GGT activity was measured in triplicate using the MaxDiscovery™ gamma-4
Glutamyl Transferase (GGT) Enzymatic Assay Kit (Bioo scientific) based on 5
the manufacturer’s instructions. Mouse embryonic feeders were used as a 6
negative control. The equivalent serum GGT activity in IU/L was calculated 7
following the manufacturer’s instructions by multiplying the average increase 8
in absorbance over 10 minutes by 353. Error bars represent SD. Multiple 9
mean absorbance comparisons (CLCs vs. substrate, CLCs vs. MEFs, CLCs 10
vs. human serum) were performed using one-way ANOVA with Dunnett 11
correction for multiple comparisons.12
Alkaline Phosphatase staining13
Alkaline phosphatase was carried out using the BCIP/NBT Color 14
Development Substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 15
tetrazolium) (Promega) according to the manufacturer’s instructions.16
Effect of Secretin, Somatostatin, Octreotide and VX809 on organoid size17
Images of CLC organoids were taken using 5X magnification before and 18
following the addition of secretin (100nM, Sigma Aldrich), somatostatin 19
(100nM, Sigma Aldrich), octrotide (100nM, Sigma Aldrich) or embryo transfer 20
water serving as a negative control, at 0.5 - 2 minute intervals until organoid 21
size stabilized. To explore the impact of octreotide on the effect of secretin, 22
cells were pre-incubated for 30 minutes with octreotide. 100nM of secretin 23
(Sigma Aldrich) was subsequently added to the medium and the experiment 24
was carried out as described above. To assess the effect of VX809 on 25
25
organoid size images were taken before and 6 hours following the addition of 1
VX809 (30mM, Selleck) or embryo transfer water, serving as a negative 2
control. 3 random diameters were measured for 8 random organoids pre and 3
post treatment. Graph measurements represent percentage differences in 4
mean organoid diameter. Error bars represent SD. Statistical significance was 5
calculated using one-way ANOVA with Dunnett correction for multiple 6
comparisons. The videos available as online supplementary data were made 7
by taking images pre and post treatment at 2 minute intervals, until organoid 8
size stabilized.9
cAMP levels10
cAMP levels were measured in triplicate using the cAMP-Glo assay kit 11
(Promega) based on the manufacturer’s instructions and a P450-Glomax 96 12
microplate luminometer (Promega). Error bars represent SD. Statistical 13
significance was calculated using one-way ANOVA with Dunnett correction for 14
multiple comparisons. 15
CFTR activity16
CFTR activity was measured as previously described (37). Briefly, MQAE is a 17
fluorescent dye quenched by the presence of chloride but not affected by 18
other anions or pH changes (39). Chloride transfer across the cell membrane 19
is mainly regulated by CFTR in cholangiocytes. Therefore, cells with a 20
functional CFTR will respond to a chloride challenge by rapidly increasing 21
intracellular (and intraluminal in case of organoids) chloride concentration 22
thereby quenching MQAE fluorescence. Chloride depletion using a nitrate 23
solution will have the opposite effect.24
26
Cells were incubated with 8mM MQAE fluorescent dye (Life Technologies)1
and 5μΜ forskolin for 4 hours at 37
o
C. MQAE fluorescence is quenched in the 2
presence chloride. Standard Ringers solution containing NaCl, KCl, CaCl, 3
MgCl, glucose and hepes was used to provide a chloride challenge expected 4
to increase intracellular chloride levels in the presence of functional CFTR. 5
Modified Ringers solution consisting of NaNO3, KNO3, CaNO3, MgNO3, 6
glucose and hepes was used to promote chloride efflux and deplete 7
intracellular chloride. Live pictures were captured every minute as each 8
solution was added. To demonstrate the effect of VX809 on CFTR 9
functionality, CLC organoids were incubated with 30mM of VX809 (Selleck) 10
for 48 hours. The assay was repeated as described above in the presence 11
and absence of 7uM CFTR inhibitor-172 (Sigma-Aldrich) to confirm the 12
specificity of the compound for CFTR. Intracellular fluorescence intensity was 13
measured in 3 random areas from the wall of each organoid using ImageJ 14
software and normalized over the minimum fluorescence value for each area. 15
Error bars represent SD.16
Cytochrome p450 activity17
Cyp3A4 activity was measured using the p450-Glo assay kit (Promega) 18
according to the manufacturer’s instructions and a P450-Glomax 96 19
microplate luminometer (Promega).20
Timing of experiments on CLC organoids21
All the experiments and characterization with regards to CLCs were 22
performed on CLC organoids, following 10 days of 3D culture unless stated 23
otherwise24
Statistical analyses25
27
All statistical analyses were performed using GraphPad Prism 6 or the R 1
statistical environment. For comparison between 2 mean values a 2-sided 2
student’s t-test was used to calculate statistical significance. For comparison3
between multiple values one-way ANOVA was used with Tuckey correction 4
for multiple comparisons when comparing multiple values to each other (e.g. 5
QPCR plots) or Dunnett correction for multiple comparisons when comparing 6
multiple values to a single value (e.g. functional assays where the values are 7
compared to a negative control). The normal distribution of our values was 8
confirmed using the Kolmogorov-Smirnov test where appropriate. Further 9
information on the statistical analysis of our data is provided in Supplementary 10
table 7 (test used for each experiment/ analysis, test statistic, degrees of 11
freedom, P value).12
To smooth our data for generating the curves in figure 3g we used functional 13
data analysis theory (48) implemented in the R package 'fda' (http://cran.r-14
project.org/web/packages/fda/index.html). First, we represented our data 15
values (3 replications at each fluorescence intensity measurement) using 60 16
equidistant B-spline basis functions, and roughness penalties in the second 17
derivative (lambda=1). We used the functions create.bspline.basis and 18
smooth.fd in the interval 1-100 seconds. Then, we evaluated the mean and 19
the standard deviation of the functional data objects using the R functions 20
mean.fd and sd.fd.21
22
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Figure Legends1
2
Figure 13
Generation of Cholangiocyte Progenitors (CP) from human Induced 4
Pluripotent Stem Cells (hiPSCs). (a) Overview of the protocol used to 5
differentiate hiPSCs to Cholangiocyte Like Cells (CLC). DE: Definitive 6
endoderm, FP: Foregut progenitors, HB: Hepatoblasts, HC: Hepatocytes SB: 7
SB431542 RA: Retinoic acid. (b) Immunofluorescence (IF) analyses 8
demonstrating the expression of key hepatoblast markers as indicated, in day 9
12 hepatoblasts. Scale bars correspond to 100μm. (c) IF analyses 10
demonstrating the expression of early biliary markers by immature 11
cholangiocyte progenitors (day 16). (d) Gene expression profile of hiPSC-12
derived cells at key stages of biliary differentiation and Primary 13
Cholangiocytes (PCs). n=4 biological replicates for each stage of 14
differentiation. n=3 independent samples for PCs. Error bars represent 15
standard deviation. Asterisks represent statistical significance of differences 16
between HBs, CPs and CLCs (one-way ANOVA with Tuckey correction for 17
multiple comparisons). 18
19
Figure 220
Generation of cholangiocyte-like cells (CLCs) from cholangiocyte progenitors 21
(CPs). (a,b) Immunofluorescence (IF) (left) and light microscopy (right) 22
images of CLC organoids (day 26) demonstrating the formation of cystic (a)23
and branching (arrows) tubular structures (b). Scale bars correspond to 24
100μm. (c) Transmitted electron microscopy images (right) and IF analyses 25
37
(left) for acetylated alpha-tubulin demonstrating the presence of cilia (arrow). 1
The IF image was acquired from the bottom of a large cystic organoid using 2
confocal microscopy.  Scale bars: 500 nm and 100μm respectively. L: Lumen. 3
(d) IF analyses demonstrating the expression of early and mature biliary 4
markers in day 25 CLCs as indicated. Scale bars: 100μm. (e) Euclidian 5
hierarchical clustering analysis focusing on the genes that define the 6
transcriptional signature of CLCs and HBs (4963 genes differentially 7
expressed in CLCs vs. hiPSCs or in HBs vs. hiPSCs). For each probe,8
standard scores (z-scores) indicate the differential expression measured in 9
number of standard deviations from the average level across all the samples. 10
CLCs cluster closer and present higher correlation coefficient with Common 11
Bile Duct cholangiocytes (CBD) used as a primary control, compared to HBs 12
or hiPSCs (Pearson, CLCs vs. PCs r = 0.747, CLCs vs. HBs r = 0.576, CLCs 13
vs. hiPSCs r = 0.474). Representative genes are indicated. The data 14
corresponds to biological triplicates.15
16
Figure 317
Functional characterization of CLC organoids (a) Representative images 18
demonstrating the MDR1 fluorescent substrate Rhodamine123 detected in the 19
lumen of CLC organoids, confirming MDR1 functionality. Scale bars 20
correspond to 100μm. (b) Fluorescence intensity measurements along the 21
area indicated by the red line. (c) Mean intra-luminal fluorescence intensity 22
normalized over background, in the presence (+VER) or absence (-VER) of 23
verapamil, n=599 measurements, P=2.99x10
-5
(2-tailed t-test). (d)24
Representative images demonstrating active export of the fluorescent bile 25
38
acid cholyl-lysyl-fluorescein (CLF) from the lumen of CLC organoids 1
compared to controls loaded with Fluorescein Isothiocyanate (FITC). (e)2
Fluorescence intensity along the area indicated by the red line. (f) Mean intra-3
luminal fluorescence intensity normalized over background, n=1163 4
measurements, P<1x10
-18
(2-tailed t-test). The data shown in panels a-f is 5
representative of 3 different experiments. (g) Fluorescence intensity 6
measurements (top) and representative fluorescence microscopy images 7
(bottom) of CLC organoids loaded with the calcium indicator Fluo-4, 8
demonstrating an increase in intracellular calcium levels following stimulation 9
with ATP and acetylcholine. Plated primary cholangiocytes stimulated with 10
ATP are used as a positive control. Grey area represents 1 SD, n=3. (h, i)11
Fold change over starting number of cells (h) and IF analyses for the 12
proliferation marker Ki-67 (i) in the presence and absence of VEGF for 5 13
days, demonstrating that VEGF promotes CLC proliferation. Prim. Chol.: 14
Plated primary cholangiocytes, n=10, p=4.77x10
-17
(CLCs), p=4.63x10
-17
15
(Prim. Chol.) (2-tailed t-test). (j) CLC organoids exhibit GGT activity. MEF: 16
Mouse Embryonic Feeders, n=3, p<0.0001 for all comparisons (one-way 17
ANOVA with Dunnett correction for multiple comparisons). (k) ALP staining 18
revealing ALP activity in CLC organoids. Top: Photographs of stained wells19
(Scale bars:1cm). Bottom: Brightfield microscopy images, n=3. Scale 20
bars:100μm. Data representative of multiple lines (Figure 6a-6b, 21
Supplementary Figure 5).22
23
Figure 424
39
Activin and Notch signaling are essential for CLC organoid formation. (a)1
Number of CLC organoids following culture of CPs in matrigel in the presence 2
and absence of SB-431542, demonstrating suppression of organoid formation 3
secondary to inhibition of activin signaling. Error bars represent SD, n=4. (b)4
Live pictures demonstrating lack of organoid formation in response to SB-5
431542. Scale bars: 100μm. (c) QPCR analyses for the expression JAG1, 6
NOTCH2, and the Notch downstream target HES1 in CLC organoids vs. CP 7
cultured in matrigel in the presence of L-685,458, demonstrating reduced 8
expression of this marker in response to L-685,458, n=4. Error bars represent 9
SD. ****P<0.0001 (two-tailed t-test). (d) IF analyses for NICD in CLC 10
organoids vs. CP cultured in matrigel in the presence of L-685,458 11
demonstrating pathway activation and nuclear localization of NICD in CLC 12
organoids vs. pathway inhibition in response to L-685,458. Scale bars:100μm, 13
EL: extra-luminal space. (e) Number of CLC organoids following culture of 14
CPs in matrigel in the presence and absence of L-685,458 demonstrating a 15
significant reduction in organoid formation, following inhibition of Notch 16
signaling. Error bars represent SD, n=4. (f) Live pictures demonstrating 17
reduced organoid formation in response to L-685,458. The data shown in 18
each panel is representative of 3 different experiments.19
20
Figure 521
22
CLC organoids respond to secretin and somatostatin stimuli and reproduce 23
the effects of somatostatin analogues (octreotide) in Polycystic Liver Disease 24
(PLD) in vitro. IF (a) analysis demonstrating the expression of secretin 25
40
receptor (SCR) in CLCs. Scale bars: 100μm. (b) IF analysis demonstrating 1
the expression of somatostatin receptor 2 (SSTR2) in CLCs. Scale bars: 2
100μm. (c) Live pictures demonstrating CLC organoids pre and post 3
treatment with secretin, somatostatin, octreotide, secretin combined with 4
octreotide. Diameter measurements are shown in each image. The images 5
have been cropped to include a single cyst, but are representative of all the 6
cysts measured. (d) Effect of secretin (SC), somatostatin (SST), octreotide 7
(OCT) and the combination of secretin and octeotide on organoid diameter. 8
Error bars represent SEM, n=8, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 9
(one-way ANOVA with Dunnett correction for multiple comparisons. (e)10
Secretin treatment increases, while somatostatin and octreotide treatment 11
decrease cAMP levels in CLC organoids. Error bars represent SEM, n=3, 12
Asterisks represent statistically significant differences (one-way ANOVA with 13
Dunnett correction for multiple comparisons). (f) QPCR demonstrating the 14
expression of biliary markers in polycystic liver disease CLCs. Asterisks 15
represent statistical significance in differences between HBs, CPs and CLCs 16
(one-way ANOVA with Tuckey correction for multiple comparisons). (g,h) 17
Live images (g) and diameter measurements (h) in PLD-CLC organoids pre 18
and post treatment with octreotide or the combination of secretin and 19
octreotide, ****:P<0.0001 (one-way ANOVA with Dunnett correction for 20
multiple comparisons). The data shown is representative of 3 different 21
experiments.22
23
Figure 624
41
Modeling Cystic Fibrosis (CF) liver disease in vitro, using hiPSCs derived from 1
patients with CF. (a) QPCR analyses of CLC organoids generated from CF-2
hiPSCs (CF-CLC), demonstrating the expression of biliary markers. Asterisks 3
denote statistical significance in differences between HBs, CPs and CLCs 4
(one-way ANOVA with Tuckey correction for multiple comparisons). (b) CF-5
CLC organoids exhibit GGT activity. ****:P<0.0001 (one-way ANOVA with 6
Dunnett correction for multiple comparisons). (c) IF analyses revealing very 7
low CFTR protein expression in CF-CLC vs. wt-CLCs expressing CFTR. (d)8
MQAE fluorescence intensity normalized over the lowest intensity value. 9
MQAE fluorescence is quenched in the presence of chloride, but not affected 10
by nitrate. Changes in intracellular or intra-luminal chloride levels in response 11
to extracellular chloride levels depend on the presence of CFTR functionality. 12
MQAE fluorescence increases in response to a nitrate challenge depleting 13
extracellular chloride and decreases in response to chloride in wt- and CF-14
CLCs treated with VX809, however fails to respond to both challenges in CF-15
CLCs and CF-CLCs treated with VX809 + CFTR inhibitor-172. (e) Live images 16
demonstrating an increase in MQAE fluorescence in response to a nitrate 17
challenge, followed by a decrease in response to a chloride challenge in wt-18
CLCs and CF-CLCs treated with VX809, however MQAE fluorescence 19
remains unchanged in CF-CLCs and CF-CLCs treated with VX809 and CFTR 20
inhibitor-172. (f) Live pictures demonstrating CLC organoids pre and post 21
treatment with VX809. Diameter measurements are shown in each image. (g) 22
Effect of VX809 treatment on mean organoid diameter. Error bars represent23
SD, n=8, P=0.001, (2-tailed t-test). Images cropped to include 1 cyst, but 24
representative. All data shown is representative of 3 different experiments.25
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